Trial Profile
Assessment of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information in Korea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 20 Apr 2022 Status changed from recruiting to completed.
- 23 Dec 2020 Planned number of patients changed from 549 to 1440.
- 23 Dec 2020 Planned End Date changed from 1 Dec 2021 to 31 Dec 2021.